Risk Factors for Higher-than-Expected Residual Rivaroxaban Plasma Concentrations in Real-Life Patients

Alexander Kaserer; Andreas Schedler; Alexander Jetter; Burkhardt Seifert; Donat R. Spahn; Philipp Stein; Jan-Dirk Studt

doi:10.1055/s-0038-1639585

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2018; 118(05): 808-817
DOI: 10.1055/s-0038-1639585

Coagulation and Fibrinolysis

Schattauer GmbH Stuttgart

Risk Factors for Higher-than-Expected Residual Rivaroxaban Plasma Concentrations in Real-Life Patients

Alexander Kaserer^*

¹Institute of Anaesthesiology, University and University Hospital Zurich, Zurich, Switzerland

,

Andreas Schedler^*

¹Institute of Anaesthesiology, University and University Hospital Zurich, Zurich, Switzerland

,

Alexander Jetter

²Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland

,

Burkhardt Seifert

³Department of Biostatistics and Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

,

Donat R. Spahn

¹Institute of Anaesthesiology, University and University Hospital Zurich, Zurich, Switzerland

,

Philipp Stein

¹Institute of Anaesthesiology, University and University Hospital Zurich, Zurich, Switzerland

,

Jan-Dirk Studt

⁴Division of Haematology, University and University Hospital Zurich, Zurich, Switzerland

› Author Affiliations

Abstract

Introduction Rivaroxaban (RXA) is a direct oral factor Xa (Xa) antagonist with a short half-life and a fast onset and offset of effect. Before elective surgery, discontinuation is recommended with an interval of at least > 24 hours. In clinical practice, this is, however, not always sufficient to achieve a residual RXA plasma concentration deemed appropriate for surgery, defined as ≤ 50 mcg/L. Our study aimed at identifying factors associated with a higher-than-expected residual RXA plasma concentration in a large group of real-life patients.

Materials and Methods This retrospective single-centre study included all patients taking RXA between 2012 and 2016 where RXA plasma concentration was determined by pharmacodynamic anti-Xa assay (518 measurements in 368 patients). Medical records were reviewed. Residual RXA plasma concentrations were then compared with expected values according to a pharmacokinetic model.

Results Residual RXA plasma concentration was significantly higher-than-expected in patients with atrial fibrillation, impaired kidney function (glomerular filtration rate [GFR] < 60 mL/min), CYP3A4-, CYP2J2- and PGP-inhibitory co-medication including amiodarone. Impaired kidney function (odds ratio [OR], 2.22, 95% confidence interval [CI], 1.30–3.78, p = 0.003) and concomitant amiodarone intake (OR, 1.97, 95% CI, 1.04–3.72, p = 0.036) were significantly associated with RXA plasma concentrations > 50 mcg/L at 24 to 48 hours after the last RXA intake.

Conclusion In our group of real-life patients, impaired kidney function (GFR < 60 mL/min) and co-medication with amiodarone were independently associated with higher-than-expected residual RXA plasma concentrations. In these patients, standard intervals of RXA discontinuation may not always be sufficient before elective surgery and routine pre-operative determination of the residual RXA concentration could be advisable.

Keywords

anticoagulation - elevated plasma concentrations - risk factors - rivaroxaban

Full Text

References

References
1 Product information Xarelto®. Available at: Swissmedicinfo.ch. Accessed October 1, 2017
2 Turpie AG, Lassen MR, Davidson BL. , et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373 (9676): 1673-1680
3 Heidbuchel H, Verhamme P, Alings M. , et al; ESC Scientific Document Group. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2017; 38 (27) 2137-2149
4 Godier A, Martin AC, Leblanc I. , et al. Peri-procedural management of dabigatran and rivaroxaban: duration of anticoagulant discontinuation and drug concentrations. Thromb Res 2015; 136 (04) 763-768
5 Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 2013; 29 (7, Suppl): S24-S33
6 Kubitza D, Becka M, Mueck W. , et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010; 70 (05) 703-712
7 Kubitza D, Becka M, Roth A, Mueck W. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor. J Clin Pharmacol 2013; 53 (03) 249-255
8 Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007; 47 (02) 218-226
9 Kubitza D, Roth A, Becka M. , et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2013; 76 (01) 89-98
10 Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013; 76 (03) 455-466
11 Studt JD, Alberio L, Angelillo-Scherrer A. , et al. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels. J Thromb Haemost 2017; 15 (08) 1576-1583
12 Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53 (01) 1-16
13 Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in healthy subjects. Int J Clin Pharmacol Ther 2007; 45 (06) 335-344
14 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
15 Asmis LM, Alberio L, Angelillo-Scherrer A. , et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012; 129 (04) 492-498
16 Kreutz R. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor. Curr Clin Pharmacol 2014; 9 (01) 75-83
17 Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50 (10) 675-686
18 Tanigawa T, Kaneko M, Hashizume K. , et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet 2013; 28 (01) 59-70
19 Godier A, Dincq AS, Martin AC. , et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J 2017; 38 (31) 2431-2439
20 Chang SH, Chou IJ, Yeh YH. , et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017; 318 (13) 1250-1259
21 Steinberg BA, Hellkamp AS, Lokhnygina Y. , et al; ROCKET AF Steering Committee and Investigators. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm 2014; 11 (06) 925-932